KRAS and pancreatic ductal adenocarcinoma: Since activating mutations in KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), CRISPR/Cas was employed in a study to model complete KRAS inhibition and predict resistance mechanisms in a subset of human and mouse PDAC cells.